Tongxinluo Capsule Treatment Of Coronary Slow Flow Of Clinical Research

Coronary Atherosclerotic Heart Disease occurs when blood vessel occlusion which is caused by coronary atherosclerosis induces myocardial ischemia and hypoxia. It is referred to as Coronary Heart Disease(CHD) collectively with functional changes of coronary artery spasm, also known as ischemic heart disease. Most CHD patients present symptoms started by myocardial ischemia and hypoxia on account of coronary thrombosis whereas small patient cohorts with no significant stenosis arteries show symptoms started by distal myocardial ischemia and hypoxia led to by slow blood flow for all kinds of reasons.This article mainly focuses on the clinical application of Tongxinluo capsules for Coronary Slow Flow Phenomenon(CSFP).CSFP is detected with the help of coronary arteriongraphy, the gold standard tst of coronary heart disease and gradually recognized. CSFP refers to a Phenomenon that coronary artery disease is not detected by coronary angiography whereas distal blood perfusion delays.Clinical attention is paid to this phenomenon along with the application and popularization of coronary arteriongraphy. There is currently no specific treatment for Slow Flow Phenomenon while the pathomechanism of CSFP still remains unknown. It is traditionally regarded as Micro vascular dysfunction. Some scholars believe slow flow phenomenon is the initial stage of Coronary artery disease others consider it is associated with abnormal Endothelial metabolism. However, there is deficiency in evidence of detailed and consolidate research.The effect of routine Antinational treatment is not obvious. Tongxinluo capsule is used as primary therapy for 38 patients with CSFP from Aug 2003 to Dec 2009 coming out with significant effect. The report is as below:Methodology (1)76 study objects from Aerospace hospital of Peking University are all hospitalized CSFP patients diagnosed via coronary angiography. (2)Judkins was applied to perform coronary angiography.Trained personnel conducted observation and interview,collected patient data and completed the observation chart.(3) Statistics: Statistical analysis is performed by SPSS 17.0 using chi-square test and logistic regression analysis taking the general genda date as the enumeration data between the two sets.X2 inspection is perfromed between the two sets of data while t test is applied taking the clinical observation data as enumeration data expressed as percentages to test the difference between the two sets.X2 inspection is perfromed to acsess the qualitative difference showing ststistic significance p< 0.05.Consequence There is no significant difference shown in two sets of data's age, genda and clinical process after the inspection of x2 and t test.Both groups present with average p> 0.05 which indicates the two sets of data are comparable.(1) clinical symptoms:treatment group demonstrate significant improvement on clinical symptoms compared with control group after the therapeutic course(X2=6.408, P=0.011<0.05) with 3.322 times improvement rate by logistic regression anaysis.(2)ECG changes:treatment group demonstrate remarkable improvement compared with control group after the therapeutic course with obvious statistics significance(X2=7.930, P=0.005<0.05) with 3.980 times effective rate by logistic regression analysis.ECG changes are significant.(3) Coronary blood flow analysis by coronary angiography:treatment group demonstrate remarkable improvement compared with control group after the therapeutic course with obvious statistics significance (X2=38.609, P=0.000<0.05),representing 37.643 times improvement rate analyzed by logistic regression. TIMI flow was obviously improved.Conclusion Patients in treatment group end up with more obvious effects such as relieved chest pain, improved ECG results and normal blood flow rather than their counterparts in control group which demonstrates Tongxinluo capsule is effective in the treatment of CSFP and reliable to be popularized as a clinical application.with the in-depth research of Tongxinluo capsule,its clinical practice can be extended to present inspiration for the treatment of Coronary Heart Disease by integrated traditional Chinese and western medicine.